Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Common Equity (2016 - 2025)

Ani Pharmaceuticals' Common Equity history spans 16 years, with the latest figure at $540.7 million for Q4 2025.

  • For Q4 2025, Common Equity rose 33.95% year-over-year to $540.7 million; the TTM value through Dec 2025 reached $540.7 million, up 33.95%, while the annual FY2025 figure was $540.7 million, 33.95% up from the prior year.
  • Common Equity for Q4 2025 was $540.7 million at Ani Pharmaceuticals, up from $505.8 million in the prior quarter.
  • Across five years, Common Equity topped out at $540.7 million in Q4 2025 and bottomed at -$62.3 million in Q1 2024.
  • The 5-year median for Common Equity is $97.4 million (2021), against an average of $182.3 million.
  • The largest annual shift saw Common Equity skyrocketed 50651200.0% in 2023 before it tumbled 115.26% in 2024.
  • A 5-year view of Common Equity shows it stood at $387.8 million in 2021, then plummeted by 100.0% to $1000.0 in 2022, then skyrocketed by 100.0% to $2000.0 in 2023, then skyrocketed by 20183900.0% to $403.7 million in 2024, then soared by 33.95% to $540.7 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Common Equity are $540.7 million (Q4 2025), $505.8 million (Q3 2025), and $3.3 million (Q2 2025).